MedTrace Logo

Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

NCT04161053 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-11-13

No results posted yet for this study

Summary

Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

Rifaximin

Rifaximin 550 mg twice daily for 6 months

DRUG

Nitazoxanide

Nitazoxanide 500 mg twice daily for 6 months

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Khadija Ahmed Glal, Msc · Tanta University

  • Tarek Mohamed Mostafa, ass, Prof. · Tanta University

  • Sherief Abd-Elsalam, Ass. Prof. · Tanta University - Tropical Medicine Department

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2028-11-30
Completion
2028-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161053 on ClinicalTrials.gov